In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach
2024
Designing New Drugs for Breast Cancer Treatment
publication
10 minutes
Evidence: moderate
Author Information
Author(s): La Monica Gabriele, Alamia Federica, Bono Alessia, Mingoia Francesco, Martorana Annamaria, Lauria Antonino
Primary Institution: University of Palermo
Hypothesis
Can dual inhibition of estrogen receptors and Hsp90 provide a new therapeutic strategy for ER+ breast cancer?
Conclusion
The study identifies compound 755435 as a promising dual inhibitor for overcoming resistance in ER+ breast cancer.
Supporting Evidence
- Compound 755435 showed high stability in complex with both ER and Hsp90.
- The study utilized advanced computational tools for drug discovery.
- Multitarget drugs can potentially reduce the risk of developing resistance.
- Simultaneous inhibition of ER and Hsp90 may enhance therapeutic efficacy.
Takeaway
Researchers are trying to find new medicines that can stop breast cancer by blocking two important proteins at the same time.
Methodology
The study used a hybrid in silico virtual screening approach to identify new dual ER/Hsp90 inhibitors, followed by molecular docking and dynamics simulations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website